[365] engineered an exosome formulation encapsulating catalase mRNA, which, upon intravenous administration, specifically targeted the brains of 6‐OHDA‐induced PD mouse models, leading to significant reductions in neurotoxicity and neuroinflammation. This evidence concerns the gene CAT and Parkinson disease.